Chimeric Antigen Receptor T cell (CAR T cell) therapy has proven to be very promising for blood disorders and potentially, for solid tumors. In this approach, T cells taken from a patient or a donor are engineered to express a receptor on their surface, which allows them to target specific domains present on cancer cells. Single-cell multi-omics techniques are being increasingly used in this exciting area, to study cellular heterogeneity and molecular signatures. Further, multi-omics techniques are also expected to provide an enhanced understanding of the interactions between CAR T cells and the host immune system.
In this webinar, Dr. Fabio Luciani from the UNSW Cellular Genomics Future Institute, Sydney, Australia, talks about how the BD™ AbSeq technology with 40 markers simultaneously, and the BD Rhapsody™ instrument were used to analyse cryo-preserved blood samples from patients undergoing CAR T cell therapy. Dr. Luciani talks about the workflow that was used, comprising of sample preparation, cell type identification and gene expression analyses. Further, Dr. Luciani describes the bioinformatics workflow that used the gene and protein expression data to analyse cellular composition. He also explains how the datasets from different specimens could be combined, to get an insight into cellular heterogeneity across samples.